TY - JOUR
T1 - Co-expression of plexin-B1 and Met in human breast and ovary tumours enhances the risk of progression
AU - Valente, Guido
AU - Nicotra, Giuseppina
AU - Arrondini, Marisa
AU - Castino, Roberta
AU - Capparuccia, Lorena
AU - Prat, Maria
AU - Kerim, Simonetta
AU - Tamagnone, Luca
AU - Isidoro, Ciro
PY - 2009
Y1 - 2009
N2 - Background: Plex-B1, the receptor of Sema4D, has been implicated in tumour growth, angiogenesis and metastasis. The binding of Sema4D to Plex-B1 can trigger the activation of Met tyrosine kinase, thereby promoting cell dissociation and invasive growth. We tested the hypothesis that the expression of Plex-B1, either alone or in association with Met, can be of predictive value for tumour progression. Methods: The expression and distribution of Plex-B1 and Met were investigated by immunohistochemistry and immunofluorescence in 50 human neoplasias originating in the breast and ovary, and correlated with clinical-pathological data at diagnosis. Results: Plex-B1 and Met were individually expressed in 14% and in 24% of the tumours, respectively. Plex-B1 and Met were co-expressed in 24/50 cases (48%), and in the majority of these (83%) Met was tyrosine phosphorylated. The expression of Plex-B1 or Met alone showed no significant correlation with tumour aggressiveness, whereas advanced stage tumours (III-IV) frequently showed Plex-B1-Met double-positive (9/13). Tumours co-expressing Plex-B1 and Met were characterised by worse grading and higher incidence of lymph node metastases. Out of 22 tumours with lymph node metastases, as many as 19 were Plex-B1 and Met double-positive (p=0.0008), and 17 expressed phosphorylated Met (p=0.002). Conclusion: Plex-B1 assumes a predictive value for unfavourable outcome when co-expressed with Met.
AB - Background: Plex-B1, the receptor of Sema4D, has been implicated in tumour growth, angiogenesis and metastasis. The binding of Sema4D to Plex-B1 can trigger the activation of Met tyrosine kinase, thereby promoting cell dissociation and invasive growth. We tested the hypothesis that the expression of Plex-B1, either alone or in association with Met, can be of predictive value for tumour progression. Methods: The expression and distribution of Plex-B1 and Met were investigated by immunohistochemistry and immunofluorescence in 50 human neoplasias originating in the breast and ovary, and correlated with clinical-pathological data at diagnosis. Results: Plex-B1 and Met were individually expressed in 14% and in 24% of the tumours, respectively. Plex-B1 and Met were co-expressed in 24/50 cases (48%), and in the majority of these (83%) Met was tyrosine phosphorylated. The expression of Plex-B1 or Met alone showed no significant correlation with tumour aggressiveness, whereas advanced stage tumours (III-IV) frequently showed Plex-B1-Met double-positive (9/13). Tumours co-expressing Plex-B1 and Met were characterised by worse grading and higher incidence of lymph node metastases. Out of 22 tumours with lymph node metastases, as many as 19 were Plex-B1 and Met double-positive (p=0.0008), and 17 expressed phosphorylated Met (p=0.002). Conclusion: Plex-B1 assumes a predictive value for unfavourable outcome when co-expressed with Met.
KW - CD100
KW - Lymph node metastases
KW - Met
KW - Plexin-B1
KW - Tumour prognosis
UR - http://www.scopus.com/inward/record.url?scp=71949109556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71949109556&partnerID=8YFLogxK
U2 - 10.3233/CLO-2009-0504
DO - 10.3233/CLO-2009-0504
M3 - Article
C2 - 19940359
AN - SCOPUS:71949109556
VL - 31
SP - 423
EP - 436
JO - Cellular oncology (Dordrecht)
JF - Cellular oncology (Dordrecht)
SN - 2211-3428
IS - 6
ER -